Marty Bonick, Chief Executive Officer, has over 20 years of leadership experience in both for‐profit and non‐profit settings. Prior to joining PhyMed, Mr. Bonick was president of division operations at Community Health Systems (CHS), overseeing a $4.5 billion portfolio of 36 hospitals and their associated clinics, outpatient centers, ambulatory surgery centers and urgent care operations across six states. Mr. Bonick also served as CEO of Jewish Hospital and Senior Vice President of Operations for Jewish Hospital & St. Mary’s Healthcare in Louisville, Ky. He has also held various leadership positions at Ardent Health Services, including CEO of Oklahoma State University Medical Center and VP of Operations for Hillcrest Medical Center in Tulsa, OK.
Dr. Forrest is the Chief Medical Officer and a PhyMed Board member. He has been a physician with Anesthesia Medical Group (AMG) since 1999. Dr. Forrest manages PhyMed’s clinical oversight including operations and quality programs. He has held multiple administrative roles within the practice to include Chief of Anesthesia and President of the AMG Board of Directors for six years.
Mr. Daniel, Chief Financial Officer, has over 30 years of financial leadership experience with an emphasis on healthcare organizations. Throughout his career, Daniel has specialized in guiding organizations through transformative growth initiatives, including mergers and acquisitions, facilitating strategic alliances, and spearheading process improvement efforts. Prior to PhyMed, Daniel was CFO of Comprehensive Pharmacy Solutions, and he has also served as CFO at American Pathology Partners. He has also held leadership roles at various laboratory and specialty pharmacy companies throughout his career. Daniel holds a Bachelor of Science degree in Accounting from Freed-Hardeman University and is a Certified Public Accountant.
Mr. Morgan develops and leads PhyMed’s new business growth strategy focusing on adding new anesthesia service contracts at hospitals and ASCs. His extensive business experience in accounting and finance, legal, sales, operations and management has been focused in the anesthesia sector of healthcare since 2004. Most recently, Mr. Morgan was the CFO at FOAA Anesthesia Services in Virginia and previously led business development with Premier Anesthesia.
Ms. Carlisle manages Human Resources, Organizational Development and Credentialing departments at PhyMed. Prior to joining PhyMed, she was the Vice President of Human Resources and Organizational Development for Renal Advantage Inc. when the company grew from $250 million to a billion dollar company.
Mr. Dorr heads the strategic management of PhyMed’s information technology resources and infrastructure. He began his career at Accenture (formerly Andersen Consulting) where he spent eight years building high performing teams across the sectors of healthcare, communications and resources. Prior to joining PhyMed, Mr. Dorr was Assistant VP within Information Technology at Ardent Health Services.
Dr. Dalton manages the clinical quality improvement activities of PhyMed, coordinating practice-wide processes designed to raise the standards of the delivery of perioperative care for the restoration or improvement of health outcomes for patients. He has been a physician partner with Anesthesia Medical Group since 1986.
Dr. Thomas has been a partner physician with AMG since 1990. He manages the implementation of compliance policies and procedures and ensures corporate compliance with federal, state and local policies. Dr. Thomas has served in many leadership positions within the group, including Chief of Anesthesiology at St. Thomas Hospital from 1992 to 2000, medical director of St. Thomas Surgicare (an outpatient surgery center) from 2002 to the present and member of the AMG Board of Directors from 1996 to 2012.
Mr. Burkhardt is responsible for executing on the company’s aggressive growth initiatives, with an emphasis on mergers and acquisitions. Prior to joining PhyMed, he served in a strategic leadership role with McKesson Specialty Health and The US Oncology Network, where he led strategic planning for a division that both partners with and invests in independent specialty practices. Previously, he served in several other corporate development and strategy roles at McKesson where his responsibilities included sourcing, negotiating and executing transactions.